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Clarification on Compounded 
Preparations
Iowa Board of Pharmacy Subrule 657 IAC 20.3(1) allows 
the compounding of a commercially available product only if 
it is necessary to meet the unique medical need of a patient. 
The complete text of that subrule is provided below. Pursu-
ant to 657 IAC 20.2, all compounding, regardless of the type 
of product, is to be done pursuant to a prescription and the 
prescription must be based on a valid pharmacist/patient/pre-
scriber relationship. Subrule 657 IAC 20.3(4) allows for the 
preparation of non-patient-specific products for “office use” if 
the product is administered to an individual patient by the pre-
scribing practitioner in a professional practice setting. Subrule 
657 IAC 20.3(4) also allows a pharmacy to prepare and sell 
to a hospital pharmacy a compounded drug product prepared 
pursuant to a prescriber’s authorization for administration to a 
specific patient. Iowa law and rules have never allowed a phar-
macy to prepare and sell to a hospital pharmacy compounded 
preparations in the absence of a prescription. Such activity is 
considered manufacturing. This would include the preparation 
of sterile products such as outsourced compounded solutions, 
IVs, or injectables. 
657 Iowa Administrative Code – 20.3(1) Compound-
ing commercially available product. Based on the 
existence of a pharmacist/patient/prescriber relation-
ship and the presentation of a valid prescription, 
pharmacists may compound, for an individual patient, 
drug products that are commercially available in the 
marketplace, if the compounded product is changed 
to produce for that patient a significant difference, as 
authorized by the prescriber, between the compounded 
drug and the comparable commercially available drug 
product, or if use of the compounded product is in the 
best interest of the patient. “Significant difference” 
would include the removal of a dye for a medical rea-
son such as an allergic reaction. When a compounded 
product is to be dispensed in place of a commercially 
available product, the prescriber and patient shall 
be informed that the product will be compounded.
Compounding Survey
The Board has requested that all Iowa pharmacies respond 
to the following survey. Responses may be sent via e-mail to 
terry.witkowski@iowa.gov. Please respond by July 1, 2013.
1. Are you compounding prescription or over-the-counter 
(OTC) drugs at your pharmacy?
2. If you are engaged in compounding, what type of com-
pounding is being done (eg, sterile, nonsterile, OTC)?
3. Does your pharmacy ship compounded products to 
other states?
4. Are your pharmacists, technicians, or the pharmacy 
itself accredited?
5. If accredited, what is the name of the accrediting body?
6. Are all compounds dispensed pursuant to a patient-
specific prescription?
7. If compounds are distributed for “office use,” what is the 
percentage of total compounded prescription volume?
8. Does your pharmacy have a separate compounding 
area within the prescription department? If so, please 
describe.
9. Are you compounding any commercially available 
products?  If so, what products are being produced and 
in what quantities?
10. Does your pharmacy document and track adverse drug 
events associated with compounded drug products?
Board Members Retire
Pharmacist DeeAnn Wedemeyer-Oleson of Adair, IA, 
and public member Margaret (Peggy) Boyle Whitworth of 
Cedar Rapids, IA, retired from the Board on April 30, 2013. 
They served six years on the Board, beginning on May 1, 
2007. While on the Board, DeeAnn also served on the Board’s 
Rules Committee, the Patient Safety Task Force, and as vice 
chairperson of the Board. The Board extends its sincere thanks 
to DeeAnn and Peggy for their many contributions and their 
dedicated public service.
 DeeAnn Wedemeyer-Oleson    Margaret Boyle Whitworth
reporting system, and thus what appears to be a high error “rate,” 
may have a safer system.
The National Coordinating Council for Medication Error Reporting 
and Prevention published a statement refuting the use of medication 
error rates. The statement, which is posted on the council’s Web 
site (www.nccmerp.org), states the “Use of medication error rates to 
compare health care organizations is of no value.” The council has 
taken this position for the following reasons: 
 ♦ Differences in culture among health care organizations can 
lead to significant differences in the level of reporting of 
medication errors. 
 ♦ Differences in the definition of a medication error among 
health care organizations can lead to significant differences in 
the reporting and classification of medication errors. 
 ♦ Differences in the patient populations served by various 
health care organizations can lead to significant differences in 
the number and severity of medication errors occurring among 
organizations. 
 ♦ Differences in the type(s) of reporting and detection systems 
for medication errors among health care organizations can lead 
to significant differences in the number of medication errors 
recorded. 
According to the statement, the council believes that there are no 
acceptable incidence rates for medication errors. The goal of every 
health care organization should be to continually improve systems to 
prevent harm to patients due to medication errors. Pharmacies should 
monitor actual and potential medication errors that occur within their 
organization, and investigate the root cause of errors with the goal of 
identifying ways to improve the medication-use system to prevent 
future errors and potential patient harm. The value of medication 
error reporting and other data gathering strategies is to provide the 
information that allows an organization to identify weaknesses in its 
medication-use system and to apply lessons learned to improve the 
system. The sheer number of error reports is less important than the 
quality of the information collected in the reports, the organization’s 
analysis of the information, and its actions to improve the system to 
prevent harm to patients.
It is more important to create the open environment that encourages 
the reporting of errors and near errors than to develop less meaningful 
comparative error rates. 
ISMP Launches Program to Track Vaccine Errors 
ISMP has launched a National Vaccine Error Reporting Program 
(VERP) that allows health care providers to confidentially report vac-
cine administration errors and near misses. Health care providers from 
all practice settings, including pharmacies and physicians’ offices, are 
encouraged to report all mistakes related to vaccines, regardless of 
whether any harm resulted from the incident. The program will help 
ISMP “better quantify the sources of errors and advocate for vaccine 
name, labeling, device, information, and other needed product changes 
to ensure patient safety,” stated Michael Cohen, ISMP president. 
The ISMP VERP was designed with the assistance of the California 
Department of Public Health and with input from experts in the field, 
indicates ISMP. Reports sent to the ISMP VERP will be shared with 
FDA and forwarded to the vaccine manufacturer when applicable. 
ISMP also plans to work with the Centers for Disease Control and 
Prevention on information received to address vaccine-related safety. 
VERP can be accessed at http://verp.ismp.org/.
Page 2
National Pharmacy Compliance News
(Applicability of the contents of articles in the National Pharmacy Compliance News to a particular state or jurisdiction should not be assumed 
and can only be ascertained by examining the law of such state or jurisdiction.)
FDA Issues New Guidelines for Sleep Aids 
Containing Zolpidem
Food and Drug Administration (FDA) has issued new dosing 
recommendations for sleep aids containing zolpidem. The new recom-
mendations are based upon new data that shows that when taken at 
night, blood levels of zolpidem remain high enough in the morning 
to impair activities that require alertness, such as driving. The new 
guidelines halve the dosage for women because the new data showed 
that their bodies take longer to eliminate the drug.
FDA urges drug manufacturers and health care providers to follow 
the new dosing instructions, which apply to brand name and generic 
drugs containing zolpidem:
 ♦ Ambien®, EdluarTM, and Zolpimist®: 5 mg for women, 5 mg 
or 10 mg for men
 ♦ Ambien CR®: 6.25 mg for women, 6.25 mg or 12.5 mg for men
Additionally, manufacturers of these drugs have been instructed 
to follow the new guidelines and print new patient information drug 
labels containing the new recommendations.
The recommended doses of Intermezzo®, a lower dose zolpidem 
product approved for middle-of-the-night awakenings, are not chang-
ing. At the time of Intermezzo’s approval in November 2011, the 
label already recommended a lower dosage for women than for men. 
Additional details are available in an FDA Drug Safety Communica-
tion, available at www.fda.gov/Drugs/DrugSafety/ucm334033.htm.
What is the National Medication Error 
Rate? What Standards Are Available for 
Benchmarking?
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and other practitioners. ISMP 
then makes appropriate contacts with companies and regulators, 
gathers expert opinion about prevention measures, and publishes 
its recommendations. To read about the risk reduction strategies 
that you can put into practice today, subscribe to ISMP Medication 
Safety Alert!® Community/Ambulatory Care Edition by visiting www 
.ismp.org. ISMP is a federally certified patient safety organization, 
providing legal protection and confidentiality for submitted patient 
safety data and error reports. ISMP is also an FDA MedWatch partner. 
Call 1-800/FAIL-SAF(E) to report medication errors to the ISMP 
Medication Errors Reporting Program or report online at www.ismp 
.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, PA 19044. 
Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
A national or other regional medication error rate does not exist. 
It is not possible to establish a national medication error rate or set a 
benchmark for medication error rates. Each pharmacy organization 
is different. The rates that are tracked are a measure of the number of 
reports at a given organization, not the actual number of events or 
the quality of the care given. Most systems for measuring medication 
errors rely on voluntary reporting of errors and near-miss events. Stud-
ies have shown that even in good systems, voluntary reporting only 
captures the “tip of the iceberg.” For this reason, counting reported 
errors yields limited information about how safe a pharmacy actu-
ally is. It is very possible that a pharmacy organization with a good 
Page 3
National Pharmacy Compliance News
(Applicability of the contents of articles in the National Pharmacy Compliance News to a particular state or jurisdiction should not be assumed 
and can only be ascertained by examining the law of such state or jurisdiction.)
Providers Should Ensure Only Diluted Forms of 
Acetic Acid Are Used, ISMP Warns 
ISMP has issued a National Alert Network (NAN) notice advising 
that health care organizations should take immediate steps to ensure 
that only diluted acetic acid solutions are used in patient care. ISMP 
advises that the use and purchase of glacial acetic acid, the most con-
centrated form of acetic acid available, should be eliminated. Several 
cases of severe burns, scarring, and other permanent damage to skin 
or mucous membranes due to the inadvertent application of glacial 
acetic acid have been reported to the National Medication Errors 
Reporting Program operated by ISMP. ISMP provides the following 
steps for preventing further such events:
 ♦ Remove glacial acetic acid, which has no use in its current 
form in clinical medicine, from the pharmacy and replace with 
vinegar (5% solution) or commercially available diluted acetic 
acid 0.25% (for irrigation) or 2% (for otic use).
 ♦ Restrict purchasing so that pharmacy staff is purchasing acetic 
acid for all procedural areas.
 ♦ Restrict choices for purchasing so that glacial acetic acid is not 
selected by mistake.
 ♦ Ensure the correct strength is ordered.
 ♦ Educate staff about the differences between glacial acetic acid 
and diluted forms of acetic acid.
 ♦ Order 5% as “vinegar,” which reduces the potential for confu-
sion with glacial acetic acid.
 ♦ Verify the product by requiring an independent double-check of 
acetic acid solutions before dispensing or applying the product.
Information on the cases reported and common reasons for the 
cases are included in the NAN alert, which is available on the ISMP 
Web site at www.ismp.org/NAN/files/20130121.pdf.
New FDA Training Video 
FDA Drug Info Rounds, a series of online training videos, provides 
important and timely drug information to practicing clinical and com-
munity pharmacists so they can help patients make better medication 
decisions. In the latest Drug Info Rounds video, pharmacists discuss 
how FDA Drug Safety Communications let health care providers, 
patients, and consumers know about newly observed potential risks 
of FDA-approved drugs. Drug Info Rounds videos are developed with 
contributions from pharmacists in FDA’s Center for Drug Evaluation 
and Research, Office of Communications, and Division of Drug 
Information and are available on the FDA Web site at www.fda.gov/
Drugs/ResourcesForYou/HealthProfessionals/ucm211957.htm.
Progress Made in Implementing 
Recommendations Intended to Prevent 
Acetaminophen Overdose 
Compelling progress has been made by stakeholders seeking to 
address the public health issue of acetaminophen overdose, indicates 
a white paper published by the National Council for Prescription 
Drug Programs (NCPDP). In 2011, NCPDP made recommendations 
that the health care industry take actions to support the safe use of 
acetaminophen, including recommending that pharmacies produce 
prescription labels with the complete spelling of acetaminophen 
and eliminating use of abbreviations such as “acet” or “APAP.” 
Previous to that, in July 2010, the National Association of Boards of 
Pharmacy® (NABP®) recommended that “state boards of pharmacy 
prohibit the use of the abbreviation ‘APAP’ on prescription labels, and 
require that ‘acetaminophen’ be spelled out to assist in preventing the 
well-recognized danger of acetaminophen induced hepatotoxicity.” 
The recommendation was based on established policy and a letter, sent 
by FDA to state boards of pharmacy, regarding the pharmacist’s role in 
educating patients about acetaminophen induced hepatotoxicity caused 
by unintentional overdose. The recommendation was also consistent 
with the report of the NABP Task Force on Uniform Prescription La-
beling Requirements, which made recommendations to encourage use 
of prescription labels that are organized in a patient-centered manner. 
NCPDP reports that pharmacy retailers “estimated to collectively 
represent more than half of the prescriptions dispensed in 2011, have 
either implemented or committed to a phased implementation” of 
the recommendation to use the complete spelling of acetaminophen 
on prescription labels. “This update to our white paper provides ad-
ditional guidance for those industry stakeholders who have not yet 
implemented the new pharmacy labeling practices for acetaminophen-
containing medicines,” states Lee Ann Stember, president, NCPDP. 
The updated white paper is accompanied by a bulletin (PDF), avail-
able at www.ncpdp.org/pdf/wp/NCPDPAcetaminophenInfoBulletin_ 
PharmacyStakeholders.pdf, developed for pharmacists that summa-
rizes some of NCPDP’s key recommendations regarding acetamino-
phen. In addition, the white paper, available for download at www 
.ncpdp.org/ind_WP.aspx, includes a list of resources for pharmacists 
to use in educating staff and pharmacy staff to use in educating 
patients (see Appendix D of the white paper). More information is 
available in an NCPDP news release available at www.ncpdp.org/
press/013113_NCPDP_Acetaminophen%20WP_FINAL.pdf.
Pharmacists Rated High for Honesty and Ethical 
Standards in Gallup’s 2012 Poll 
Pharmacists ranked as the second most trusted profession in the 
2012 Gallup Poll that asked consumers to rate 22 professions accord-
ing to their honesty and ethical standards. Pharmacists were ranked 
as very high or high in this category by 75% of those surveyed, with 
nurses ranking first at 85%, and medical doctors third at 70%. Ad-
ditional information on the results of the 2012 poll is available on the 
Gallup Web site at www.gallup.com/poll/159035/congress-retains-
low-honesty-rating.aspx.
 
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
Continuing pharmacy education (CPE) providers who are accredited 
by the Accreditation Council for Pharmacy Education (ACPE) have 
integrated CPE Monitor® into their systems and are requiring pharmacists 
and pharmacy technicians to provide an NABP e-Profile ID number and 
date of birth (MMDD) in order to process ACPE-accredited CPE credit.
Visit www.MyCPEmonitor.net to set up your NABP e-Profile and register 
for CPE Monitor and avoid possible delays in your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
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New Board Members Appointed
Congratulations to pharmacist Sharon Meyer of Urban-
dale, IA, and public member Judy Trumpy of Ames, IA, on 
their appointment to three-year terms on the Iowa Board of 
Pharmacy by Governor Terry Branstad effective May 1, 2013.
Sharon Meyer is a graduate of 
Creighton University with a doc-
tor of pharmacy degree and she 
completed a fellowship in family 
practice at Creighton University. 
She also has a master’s in health 
services management from Clark-
son College. She is employed 
by Cardinal Health Pharmacy 
Solutions. Her current position 
is a shared position working as a 
pharmacy analyst with UnityPoint 
Health IT and working as a senior project manager with Unity-
Point Health – Des Moines. Prior to this position, she was the 
executive director of pharmacy for Iowa Health – Des Moines 
(now known as UnityPoint Health – Des Moines) for 10 years. 
Judy Trumpy is a native Iowan 
and a graduate of Iowa State Uni-
versity (ISU) in food and nutri-
tion – dietetics. Judy has over 44 
years of experience practicing in 
hospitals, long-term care settings, 
and lastly, 20 years with ISU Din-
ing as an assistant manager and a 
nutrition counselor at the Thielen 
Student Health Center. Judy com-
pleted her dietetic internship with 
the US Army Medical Department 
and served an additional year as chief of diet therapy at the 
US Army Hospital in Ft Carson, CO. She recently joined the 
American Legion in Ames, Post 37, and is a member of the 
honor guard.
Election of Board Officers
The Board has elected Ed Maier of Mapleton, IA, as Board 
chairperson for a one-year term beginning May 1, 2013. Jim 
Miller of Dubuque, IA, was elected vice chairperson for the 
same term.
Board Web Site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and 
protects the public health, safety, and welfare through the 
effective regulation of the practice of pharmacy and the li-
censing of pharmacies, pharmacists, and others engaged in 
the sale, delivery, or distribution of prescription drugs and 
devices. Iowa Code §155A.2(1).
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Pictured left to right: Pete Fay, LaDonna Gratias, Mark 
Oleson, Jim Miller, Brenda Halling, DeeAnn Wedemeyer-
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